Viral vectors
Viruses have become some of the most efficient vehicles for transferring genetic information into eukaryotic cells. In this context, molecular biologists have devoted much effort to modifying their genome to make them safer (incompetent for replication, attenuation) but maintaining their abilities to transfer and express recombinant genetic material. Thus, viral vectors have become a very useful tool in biomedical research both in vitro (cell cultures) and in vivo (experimental animals, gene therapy). However, we should be aware that the improvements in the intrinsic biosafety and the commercial availability of these vectors can facilitate a relaxation in the application of safety practices, a circumstance that must be avoided.
Working with viral vectors
The viruses from which the viral vectors are derived may be assigned to risk group 1 (e.g. Adeno-Associated Virus, Baculovirus), group 2 (e.g. Adenovirus, Herpesvirus, Poxvirus) and even to risk group 3 (e.g. HIV). In general, the biosafety level required to work with viral vectors is BSL2 but this may vary depending on the proposed experimental procedure (e.g. large-scale production, animal inoculation) or the biological activity of the transgene (e.g. oncogene, biotoxin).
Therefore, an accurate risk assessment in working with viral vectors must consider: a) the risk group of the unmodified parental virus; b) the degree of modification made to obtain the defective vector; c) the function of the inactivated viral genes; d) pseudotyping/host range; e) changes in their ability and efficiency to integrate into the host chromosomes; and f) the function of the transgene.
The IBC offers a online course and informative material for carrying out an accurate risk assessment to all UAB research staff working with viral vectors. Among this material we highlight the Pathogen Safety Data Sheets and Fact Sheets.
- Viruses and Viral Vectors (Stanford University).
- Lentiviral Vectors (Canadian Biosafety Guideline 2019).
- Lentivirus Vector Fact Sheet (ABSA).